Claims
- 1. A vesicle, comprising:
ATP, and a phospholipid which is a stable vesicle former, wherein the vesicle has a fusion rate of at least 20 vesicle fusions/second:
- 2. The vesicle of claim 1, further comprising another polar lipid.
- 3. The vesicle of claim 1, further comprising at least one member selected from the group consisting of PEG, a raft former and a fusion protein.
- 4. The vesicle of claim 2, wherein the phospholipid or the another polar lipid has the structure of formula (I)
- 5. The vesicle of claim 1, wherein the fusion rate is at least 103 vesicle fusions/second.
- 6. The vesicle of claim 4, wherein
A is H, or has a structure selected from the group consisting of formulas (III), (IV), (V), (VI) and (VII) 12L has a structure selected from the group consisting of formulas (VIII), (IX) or 13and E has a structure selected from the group consisting of (XII), (XIII), (XIV), (XV) or (XVI) 14
- 7. The vesicle of claim 6, wherein the phospholipid is 1,2-dioleoyl-sn-glycero-3-phosphocholine, 1-palmitoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine, or a mixture thereof.
- 8. A vesicle, comprising:
a phospholipid which is stable vesicle former, and at least one member selected from the group consisting of another polar lipid, PEG, a raft former and a fusion protein, wherein the vesicle has a fusion rate of at least 20 vesicle fusions/second.
- 9. The vesicle of claim 8, wherein the at least one member is another polar lipid, and the vesicle further comprises at least one member selected from the group consisting of PEG, a raft former and a fusion protein.
- 10. The vesicle of claim 8, wherein the phospholipid or the another polar lipid has the structure of formula (I)
- 11. The vesicle of claim 8, wherein the fusion rate is at least 103 vesicle fusions/second.
- 12. The vesicle of claim 10, wherein
A is H, or has a structure selected from the group consisting of formulas (III), (IV), (V), (VI) and (VII) 17L has a structure selected from the group consisting of formulas (VIII), (IX) or 18and E has a structure selected from the group consisting of (XII), (XIII), (XIV), (XV) or (XVI) 19
- 13. The vesicle of claim 12, wherein the phospholipid is 1,2-dioleoyl-sn-glycero-3-phosphocholine, 1-palmitoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine, or a mixture thereof.
- 14. A vesicle, comprising:
ATP, and a phospholipid which is stable vesicle former, wherein the phospholipid has the structure of formula (I′) X′-L′-Z′2 (I′) wherein X′ has a structure of formula (II′) 20B′ is a cation or an alkyl group, A′ is an alkyl group, L′ is an alkyl further missing two hydrogen atoms, and one Z′ is E″, or the structure of formula (XI″), 21wherein E″ is an alkyl or alkenyl, and the other Z is E′, or the structure of formula (XI′) 22wherein E′ is an alkenyl.
- 15. The vesicle of claim 14, further comprising another polar lipid.
- 16. The vesicle of claim 14, further comprising at least one member selected from the group consisting of PEG, a raft former and a fusion protein.
- 17. The vesicle of claim 15, wherein the another polar lipid has the structure of formula (I)
- 18. The vesicle of claim 17, wherein
A is H, or has a structure selected from the group consisting of formulas (III), (IV), (V), (VI) and (VII) 25L has a structure selected from the group consisting of formulas (VIII), (IX) or 26and E has a structure selected from the group consisting of (XII), (XIII), (XIV), (XV) or (XVI) 27
- 19. The vesicle of claim 18, wherein the phospholipid is 1,2-dioleoyl-sn-glycero-3-phosphocholine, 1-palmitoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine, or a mixture thereof.
- 20. A vesicle, comprising:
a phospholipid which is stable vesicle former, and and at least one member selected from the group consisting of a polar lipid which is not a stable vesicle former and PEG, wherein the phospholipid which is stable vesicle former has a structure of formula X-L-Z2 (I) wherein X is H, or has a structure of formula (II) 28B is a cation or an alkyl group, A is a H or an alkyl group, L is an alkyl further missing two hydrogen atoms, and each Z is independently H, E, or the structure of formula (XI), 29wherein E is an alkyl or alkenyl, and when one Z is H, the other Z is not H.
- 21. The vesicle of claim 20, wherein
A is H, or has a structure selected from the group consisting of formulas (III), (IV), (V), (VI) and (VII) 30L has a structure selected from the group consisting of formulas (VIII), (IX) or 31and E has a structure selected from the group consisting of (XII), (XIII), (XIV), (XV) or (XVI) 32
- 22. The vesicle of claim 20, wherein the phospholipid is 1,2-dioleoyl-sn-glycero-3-phosphocholine, 1-palmitoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine, or a mixture thereof
- 23. The vesicle of claim 20, further comprising at least one member selected from the group consisting of a raft former and a fusion protein.
- 24. The Vesicle of claim 19, wherein the vesicle comprises the polar lipid which is not a stable vesicle former, and comprises the polar lipid which is not a stable vesicle former has a structured selected from the group consisting of formulas (XVII), (XVIII), (XIX), (XXX), (XXI), (XXII), (XXIII), (XXV) and (XXVI)
- 25. A method for delivering ATP to a cell, comprising contacting the cell with the vesicle of claim 1.
- 27. A method for delivering ATP to a cell, comprising contacting the cell with the vesicle of claim 8.
- 28. A method for delivering ATP to a cell, comprising contacting the cell with the vesicle of claim 14.
- 29. A method for delivering ATP to a cell, comprising contacting the cell with the vesicle of claim 20.
- 30. A method of preserving tissue, comprising contacting tissue with a vesicle, wherein the vesicle comprises:
a phospholipid which is a stable vesicle former, and ATP.
- 31. The method of claim 30, wherein the vesicle further comprises at least one member selected from the group consisting of a polar lipid which is not a stable vesicle former and PEG.
- 32. The vesicle of claim 30, wherein the phospholipid is 1,2-dioleoyl-sn-glycero-3-phosphocholine, 1-palmitoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine, or a mixture thereof.
- 33. The vesicle of claim 30, further comprising at least one member selected from the group consisting of a raft former and a fusion protein.
- 34. The vesicle of claim 31, wherein the vesicle comprises the polar lipid which is not a stable vesicle former, and the polar lipid which is not a stable vesicle former has a structure selected from the group consisting of formulas (XVII), (XVIII), (XIX), (XX), (XXI), (XXII), (XXIII), (XXV) and (XXVI)
- 35. A method of delivering ATP to a cell, comprising contacting the cell with a vesicle;
wherein the vesicle comprises:
a phospholipid which is a stable vesicle former, and ATP, wherein an amount of ATP delivered to the cell is sufficient to meet metabolic demand of the cell.
- 36. A method of delivering ATP to a cell, comprising contacting the cell with the vesicle of claim 1.
- 37. A method of delivering ATP to a cell, comprising contacting the cell with the vesicle of claim 8.
- 38. A method of delivering ATP to a cell, comprising contacting the cell with the vesicle of claim 14.
- 39. A method of delivering ATP to a cell, comprising contacting the cell with the vesicle of claim 20.
- 40. A method for treating a wound, comprising contacting the wound with a composition comprising a vesicle;
wherein the vesicle comprises:
a phospholipid which is a stable vesicle former, and ATP.
- 41. A method for treating a wound, comprising contacting the wound with a composition comprising the vesicle of claim 1.
- 42. A method for treating a wound, comprising contacting the wound with a composition comprising the vesicle of claim 8.
- 43. A method for treating a wound, comprising contacting the wound with a composition comprising the vesicle of claim 14.
- 44. A method for treating a wound, comprising contacting the wound with a composition comprising the vesicle of claim 20.
- 45. The method of claim 40, wherein the composition further comprises becaplermin.
- 46. A composition comprising:
a vesicle, and becaplermin, wherein the vesicle comprises:
a phospholipid which is a stable vesicle former, and ATP.
- 47. A method of improving the productivity of a bioreactor having at least one cell, comprising contacting the cell with a vesicle,
wherein the vesicle comprises:
a phospholipid which is a stable vesicle former, and ATP.
RELATED APPLICATIONS
[0001] This application claims priority to U.S. provisional application Serial No. 60/380,762, FUSOGENIC LIPID VESICLES, to William D. Ehringer and Sufan Chien, filed May 14, 2002, which is incorporated herein by reference in its entirety.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60380762 |
May 2002 |
US |